Table 1 Baseline characteristics of non-LRRT and LRRT cohorts before matching
Characteristic | Non-LRRT cohort (N = 178) | LRRT cohort (N = 220) | P value |
|---|---|---|---|
Demographic features | |||
Median age at diagnosis, years (IQR) | 47.0 (38.0–56.3) | 46.0 (37.0–54.8) | 0.82 |
Sex | 0.94 | ||
Male | 141 (79.2) | 175 (79.5) | |
Female | 37 (20.8) | 45 (20.5) | |
Clinical characteristics | |||
Smoking | 0.46 | ||
No | 106 (59.6) | 139 (63.2) | |
Yes | 72 (40.4) | 81 (36.8) | |
Median BMI (IQR) | 22.4 (20.1–24.9) | 22.9 (20.7–25.1) | 0.78 |
ECOG PS | 0.45 | ||
0 | 111 (62.4) | 129 (58.6) | |
1 | 67 (37.6) | 91 (41.4) | |
T stage at diagnosis | 0.052 | ||
T1-2 | 11 (6.2) | 25 (11.3) | |
T3 | 100 (56.2) | 100 (45.5) | |
T4 | 67 (37.6) | 95 (43.2) | |
N stage at diagnosis | 0.035 | ||
N0-1 | 11 (6.2) | 31 (14.1) | |
N2 | 58 (32.6) | 70 (31.8) | |
N3 | 109 (61.2) | 119 (54.1) | |
No. of metastatic organs at diagnosis | 0.002 | ||
1 | 92 (51.7) | 147 (66.8) | |
>1 | 86 (48.3) | 73 (33.2) | |
No. of metastatic lesions at diagnosis | 0.027 | ||
≤3 | 74 (41.6) | 116 (52.7) | |
>3 | 104 (58.4) | 104 (47.3) | |
Bone metastasis at diagnosis | 0.64 | ||
No | 54 (30.3) | 62 (28.2) | |
Yes | 124 (69.7) | 158 (71.8) | |
Liver metastasis at diagnosis | 0.008 | ||
No | 101 (56.7) | 153 (69.5) | |
Yes | 77 (43.3) | 67 (30.5) | |
Lung metastasis at diagnosis | 0.55 | ||
No | 133 (74.7) | 170 (77.3) | |
Yes | 45 (25.3) | 50 (22.7) | |
Distant lymph nodes metastasis at diagnosis | 0.019 | ||
No | 128 (71.9) | 180 (81.8) | |
Yes | 50 (28.1) | 40 (18.2) | |
Response evaluation after first-line immunochemotherapy | 0.012 | ||
CR or PR | 147 (82.6) | 200 (90.9) | |
SD | 27 (15.2) | 20 (9.1) | |
PD | 4 (2.2) | 0 (0.0) | |
Serological indicators | |||
EBV DNA level at diagnosis (copies/mL) | <0.001 | ||
<95000 | 132 (74.2) | 201 (91.4) | |
≥95000 | 46 (25.8) | 19 (8.6) | |
EBV DNA level after first-line immunochemotherapy | <0.001 | ||
Undetectable | 121 (68.0) | 188 (85.5) | |
Detectable | 57 (32.0) | 32 (14.5) | |
LDH level at diagnosis (U/L) | <0.001 | ||
<500 | 146 (82.0) | 207 (94.1) | |
≥500 | 32 (18.0) | 13 (5.9) | |
ALB level at diagnosis (g/L) | <0.001 | ||
<40 | 38 (21.3) | 18 (8.2) | |
≥40 | 140 (78.7) | 202 (91.8) | |
CRP level at diagnosis (mg/L) | <0.001 | ||
<10 | 106 (59.6) | 170 (77.3) | |
≥10 | 72 (40.4) | 50 (22.7) | |
Absolute lymphocyte counts at diagnosis (109/L, IQR) | 1.49 (1.15–1.97) | 1.68 (1.37–2.19) | 0.34 |
NLR at diagnosis | 0.13 | ||
<3 | 85 (47.8) | 122 (55.5) | |
≥3 | 93 (52.2) | 98 (44.5) | |
Treatment | |||
Platinum-based chemotherapy plus anti-PD-1 antibody immunotherapy | 178 (100.0) | 220 (100.0) | |
LRRT after first-line immunochemotherapy | 0 (0.0) | 220 (100.0) | |
Failure detailsa | |||
Median progression-free interval, months (IQR) | 15.4 (8.4–26.1) | 27.2 (14.6–36.6) | |
Sustained control | 45 (25.3) | 120 (54.5) | |
Any locoregional failure | 86 (48.3) | 14 (6.4) | |
Local failure | 36 (20.2) | 9 (4.1) | |
Regional failure | 71 (39.9) | 8 (3.6) | |
Local and regional failure | 21 (11.8) | 3 (1.4) | |
Any distant failure | 79 (44.4) | 91 (41.4) | |
Bone failure | 33 (18.5) | 31 (14.1) | |
Liver failure | 34 (19.1) | 40 (18.2) | |
Lung failure | 20 (11.2) | 32 (14.5) | |
Distant lymph node failure | 24 (13.5) | 27 (12.3) | |
Development of new metastatic lesions | 18 (10.1) | 32 (14.5) | |
